logo
logo

venBio Closes $394 Million Life Sciences Venture Capital Fund

Apr 03, 2020•over 5 years ago

Amount Raised

$394 Million

San Francisco

Description

venBio Partners LLC today announced the closing of venBio Global Strategic Fund III (“venBio Fund III”), its third life sciences venture capital fund, exceeding its target and closing on approximately $394 million in capital commitments in an oversubscribed fundraise. The capital was raised from existing and new investors, including a broad range of institutional investors comprising pharmaceutical companies, corporate pensions, financial institutions, endowments and foundations, family offices and funds-of-funds.

Company Information

Company

Ven Bio Fund

Location

San Francisco, California, United States

About

Established in 2011, venBio Partners is a life science venture capital firm that focuses on novel therapeutics for unmet medical needs. Since inception, venBio has raised nearly $1 billion in capital commitments and has invested in 29 companies including venBio-founded Labrys Biologics (acquired by Teva), Aragon Pharmaceuticals (acquired by Johnson & Johnson), Seragon Pharmaceuticals (acquired by Roche), Aurinia Pharmaceuticals (NASDAQ: AUPH), Apellis Pharmaceuticals (NASDAQ: APLS), Turning Point Therapeutics (NASDAQ: TPTX), Precision Biosciences (NASDAQ: DTIL) and Akero Therapeutics (NASDAQ: AKRO). For more information, please visit www.venbio.com.

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech